Sign in

    ACELYRIN Inc (SLRN)

    You might also like

    Business Description

    ACELYRIN, INC. (Nasdaq: SLRN) is a late-stage clinical biopharmaceutical company focused on developing and commercializing transformative medicines to address unmet medical needs. Headquartered in the Los Angeles area with additional operations in the San Francisco Bay area, the company specializes in identifying and accelerating the development of innovative therapies. ACELYRIN does not currently have any approved products for commercial sale and is primarily engaged in clinical development activities.

    1. Izokibep - A small protein therapeutic designed to inhibit IL-17A, currently in late-stage clinical trials for hidradenitis suppurativa, psoriatic arthritis, and uveitis, with plans for axial spondyloarthritis.
    2. Lonigutamab - A monoclonal antibody targeting the IGF-1 receptor, being developed for the treatment of Thyroid Eye Disease (TED).
    3. SLRN-517 - A monoclonal antibody targeting c-KIT, under development for chronic urticaria.

    Executive Team

    NamePositionStart DateShort Bio
    Shao-Lee LinFounder, Chief Executive Officer, DirectorJuly 2020Founder and CEO of SLRN since July 2020. Previously held leadership roles at Horizon Therapeutics, AbbVie, Gilead Sciences, and Amgen. Holds an M.D. and Ph.D. from Johns Hopkins.
    Gil LabrucherieChief Financial OfficerAugust 17, 2023CFO of SLRN since August 17, 2023, after serving as interim CFO from August 2, 2023. Previously CFO and COO at Nektar Therapeutics. Holds a J.D. from UC Berkeley and is a CFA charterholder.
    Melanie GloriaChief Operating OfficerNovember 2021COO of SLRN since November 2021. Former SVP of Development Operations at Horizon Therapeutics. Holds a B.S. in nursing from the University of Illinois, Chicago.
    Mina KimChief Legal and Administrative OfficerNovember 2022Chief Legal and Administrative Officer since November 2022. Former Chief Legal Officer at Zymergen and held senior roles at Atara Biotherapeutics and Sunrun. Holds a J.D. from Harvard Law School.
    Ron OystonChief People OfficerSeptember 2022Chief People Officer since September 2022. Previously SVP and Head of HR at SLRN and VP of HR at Horizon Therapeutics. Holds an M.B.A. from the University of Edinburgh.
    Shephard MpofuChief Medical OfficerSeptember 2023CMO of SLRN since September 2023. Former CMO of Novartis’ Gene Therapy franchise and Global Lead for secukinumab, advancing it to multiple approvals.
    Mina KimChief Executive OfficerMay 9, 2024Appointed CEO effective May 9, 2024. Previously Chief Legal and Administrative Officer at SLRN. Held senior roles at Zymergen, Atara Biotherapeutics, and Sunrun. Holds a J.D. from Harvard Law School.
    Sanam PangaliChief Legal Officer and Head of PeopleMay 9, 2024Promoted to Chief Legal Officer and Head of People effective May 9, 2024. Previously served as Senior Vice President, Corporate Legal at SLRN.

    Questions to Ask Management

    1. Given the potential for hearing-related adverse events with anti-IGF-1R agents like lonigutamab, can you elaborate on how your Phase III dosing strategy aims to mitigate these risks, and what thresholds for hearing impairment are acceptable for regulatory approval?
    2. With biologic-experienced patients included in your izokibep uveitis trial—unlike the VISUAL I study for adalimumab—how might this affect the efficacy outcomes, and how will you interpret the data in the context of these differing patient populations?
    3. Considering your cash runway projections to mid-2027 exclude new investments in izokibep, what specific criteria will you use to decide whether to advance izokibep into a Phase III uveitis trial, and how would this impact your financial guidance?
    4. How do you plan to balance further development of izokibep, given the $35.7 million manufacturing credit voucher, with your primary focus on lonigutamab, and what factors would trigger renewed investment in the izokibep program?
    5. As you plan to extend dosing of lonigutamab to 52 weeks in both active and inactive TED patients, what evidence supports the long-term safety and efficacy over this extended period, and how have regulators responded to this approach compared to standard treatment durations?